Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease
- 4 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (6) , 748-755
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)JACC, 2021
- Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohortJournal of Clinical Lipidology, 2020
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolNew England Journal of Medicine, 2020
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeJACC, 2020
- Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid AssociationJournal of Clinical Lipidology, 2019
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskCirculation, 2019
- A Test in Context: Lipoprotein(a)JACC, 2017
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General PopulationJACC, 2014
- Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery DiseaseJACC, 2014
- Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General PopulationCirculation, 2008